NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




Lung Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Non-Small Cell - Stage I

Alliance A081105 - "Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)"

CANCER TYPE: Non-Small Cell - Stage I
RESEARCH BASE: Alliance A081105
NCT NUMBER: 02193282
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB (>4cm), II, or IIIA, non-squamous, completely resected, prior regist to A151216 (ALCHEMIST); Erlotinib vs placebo.  DCP-001 Eligible






Alliance A151216 - "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)"

CANCER TYPE: Non-Small Cell - Stage I
RESEARCH BASE: Alliance A151216
NCT NUMBER: 02194738
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB, II, or IIIA, resectable, no neo-adjuv chemo or RT; Study of Enrichment Marker Identification & Sequencing (EGFR & ALK genotyping).  DCP-001 Eligible






Non-Small Cell - Stage II

Alliance A081105 - "Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)"

CANCER TYPE: Non-Small Cell - Stage II
RESEARCH BASE: Alliance A081105
NCT NUMBER: 02193282
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB (>4cm), II, or IIIA, non-squamous, completely resected, prior regist to A151216 (ALCHEMIST); Erlotinib vs placebo.  DCP-001 Eligible






Alliance A151216 - "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)"

CANCER TYPE: Non-Small Cell - Stage II
RESEARCH BASE: Alliance A151216
NCT NUMBER: 02194738
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB, II, or IIIA, resectable, no neo-adjuv chemo or RT; Study of Enrichment Marker Identification & Sequencing (EGFR & ALK genotyping).  DCP-001 Eligible






ECOG-ACRIN E4512 - "A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein"

CANCER TYPE: Non-Small Cell - Stage II
RESEARCH BASE: CTSU E4512
NCT NUMBER: 02201992
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 09/21/2018 (21:18:18)

BRIEF DESCRIPTION

NSC, Stg IB (>4cm), II, or IIIA, non-squamous, completely resected, prior regist to A151216 (ALCHEMIST); Crizotinib vs placebo.  DCP-001 Eligible






Non-Small Cell - Stage IIIA

Alliance A081105 - "Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)"

CANCER TYPE: Non-Small Cell - Stage IIIA
RESEARCH BASE: Alliance A081105
NCT NUMBER: 02193282
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB (>4cm), II, or IIIA, non-squamous, completely resected, prior regist to A151216 (ALCHEMIST); Erlotinib vs placebo.  DCP-001 Eligible






Alliance A151216 - "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)"

CANCER TYPE: Non-Small Cell - Stage IIIA
RESEARCH BASE: Alliance A151216
NCT NUMBER: 02194738
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB, II, or IIIA, resectable, no neo-adjuv chemo or RT; Study of Enrichment Marker Identification & Sequencing (EGFR & ALK genotyping).  DCP-001 Eligible






Non-Small Cell - Stage IV

NRG-LU002 - "Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial."

CANCER TYPE: Non-Small Cell - Stage IV
RESEARCH BASE: NRG
NCT NUMBER: NCT03137771
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 09/05/2018 (19:15:54)

BRIEF DESCRIPTION

NSCLC, Stage IV, partial response to 1st line tx, measurable disease, 3 or fewer discrete, extracranial metastatic disease sites, maintenance systemic therapy +/- SBRT.






SWOG S1400 - "A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer"(Lung-Map)

CANCER TYPE: Non-Small Cell - Stage IV
RESEARCH BASE: SWOG S1400
NCT NUMBER: NCT02154490
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
Additional Consent Form: VIEW CONSENT FORM 2
BRIEF DESCRIPTION

Squamous cell lung ca, Stg IV or recurrent, 1 prior front-line platinum-based chemo regimen w/disease progression; CLIA Biomarker Profiling ---> sub-study assignments based on results. Mandatory tissue submission & Central Review of scans.  DCP-001 Eligible






SWOG S1400F - "A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)"

CANCER TYPE: Non-Small Cell - Stage IV
RESEARCH BASE: SWOG
NCT NUMBER: NCT03373760
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 08/17/2018 (16:13:55)

BRIEF DESCRIPTION

Stage IV or recurrent, PDL-1 positive, Durvalumab and Tremelimumab.  DCP-001 Eligible






SWOG S1400K - "A Phase II Study of ABBV-399 in Patients with C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)"

CANCER TYPE: Non-Small Cell - Stage IV
RESEARCH BASE: SWOG
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Stage IV or recurrent,C-Met positive, SCCA, ABBV-399.  DCP-001 Eligible









  © 2013-2018 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA